Thrombotic and hemorrhagic complications frequently have been observed in patients with monoclonal gammopathy, Waldenström macroglobulinemia, amyloidosis, multiple myeloma (MM), and myeloma. Chemotherapy in combination with the use of antiangiogenic agents can further enhance the risk of cardiovascular complications. A malignancy-associated thrombophilic state (in particular, cytokine-induced high levels of factor VIII and von Willebrand factor) can also explain the high rate of thrombosis reported in these patients. Impaired fibrinolysis and a transient downregulation of the protein C system are recently discovered pathogenetic mechanisms. At diagnosis, when the highest VTE risk is present, baseline coagulation tests such activated protein C resistance may be helpful to identify patients who can benefit the most from anticoagulation; with the emerging evidence of a positive effect on survival of low molecular weight heparin, prospective trials are needed in this group of diseases.
INCIDENCE OF THROMBOEMBOLIC COMPLICATIONS
Thrombosis is now recognized as one of the most common complications faced by cancer patients. In addition to common risk factors for venous thromboembolism (VTE) such as age, immobility, surgery, inflammatory response, and chemotherapy, disease-specific mechanisms are involved in the pathogenesis of the phenomenon. The overall incidence of VTE in the general population is 117 per 100,000 person-years. Incidence rates for both deep vein thrombosis (DVT) and pulmonary embolism (PE) increase dramatically with advancing age among both men and women. Thromboembolic complications frequently have been reported in patients with paraproteinemias, as in many other hematologic malignancies. Monoclonal gammopathy of undetermined significance (MGUS) has been associated with an increased risk of VTE: the VTE rate was 6.1% (1.3 per 100 patient-years) in a prospective analysis of 310 MGUS patients 1 and 7.5% in a retrospective study with 174 patients observed during a 10-year period. 2 With the knowledge that specific intervention can affect the hemostatic system differently, multiple myeloma (MM) patients treated with vincristine 0.5 mg, doxorubicin (doxo) 10 mg/m 2 , and dexamethasone 40 mg daily for 4 days (VAD) with or without radiotherapy showed a VTE incidence of 10%. 2, 3 In a population with a median age of 61 years, two recent large phase III trials in the relapse setting have shown that single-agent dexamethasone is associated with a low rate of thrombosis (3.5% in the MM-009 trial, 4.5% in the MM-010 trial). 4, 5 Similar incidence (3%) has been observed with dexamethasone in the newly diagnosed setting.
The recent introduction of effective antiangiogenic agents in cancer treatment has heightened the medical attention on this phenomenon. Thalidomide, the first antiangiogenic drug tested in MM, was associated to an unexpected high rate of VTE (27%) when combined with dexamethasone and chemotherapy. 7 This complication was not apparent when used as single agent: VTE incidence was < 5% in 169 extensively pretreated MM patients receiving single-agent thalidomide 8 ; a similar experience was reported by other investigators. 9, 10 Compared with single-agent thalidomide, a modest increase of the thrombotic risk was described in relapsed or refractory patients treated with the combination of dexamethasone and thalidomide (VTE rate 8%), 11 but this risk became more prominent when the same regimen was applied to newly diagnosed subjects (VTE rate 20 to 26%). 6, 12 The potential thrombogenicity of the thalidomide/chemotherapy combination was confirmed further in a phase III trial with upfront random assignment to chemotherapy with or without thalidomide: incidence of thrombosis was statistically higher in the thalidomide arm (p ¼ 0.002). 13 Among 232 MM patients treated with chemotherapy and thalidomide in two protocols that differed only by the inclusion of doxo in one, VTE incidence was significantly different in the two groups (doxo 16 versus 3.5%; p ¼ 0.02). 14 The synergistic prothrombotic effect of doxo/ thalidomide combination was also confirmed in an experimental model of thrombosis in rabbits. 15 In a multivariate analysis of 535 patients treated with thalidomide in various trials, newly diagnosed status, thalidomide/ doxo combination, and presence of chromosome 11 abnormalities were the only independent risk factors associated with DVT development. 16 The early onset of thrombosis, when the highest tumor load is present (50% of cases within 2 months), 12 indicates a possible release of thrombogenic factors from cancer cells. Low VTE rate (8%) has been reported in the United Kingdom Myeloma Forum T-VAD trial, in which thalidomide was added to VAD chemotherapy (T-VAD) only after an initial debulking with two chemotherapy cycles. 17 The low VTE incidence associated with the brief delay in thalidomide administration suggests that the drug could act as a precipitating factor only in the presence of a baseline prothrombophilic state. The immunomodulatory drug lenalidomide is a thalidomide analogue that retains direct anticancer toxicity and immunological activity of the parent compound but with different toxicity profile. Deep venous thrombosis was not a frequent event in phase I and II studies. 18, 19 However, grade 3 or 4 VTE were observed in 18% of patients enrolled in a phase II trial which compared two different lenalidomide dexamethasone schedules. 20 Preliminary reports of two multicenter double blind phase III trials which compared lenalidomide plus dexamethasone versus dexamethasone and placebo in relapsed/refractory setting (MM-009 study in North America and MM-010 study internationally) indicate statistically higher DVT incidence in the lenalidomide/ dexamethasone arms of both the studies (MM-009 15% vs 3.5% & MM-010 8.5% vs 4.5%). 4, 5 Frequent thrombotic episodes were reported in an ongoing SWOG trial which compared dexamethasone alone versus dexamethasone plus lenalidomide in newly diagnosed patients; 9 of the first 12 patients (75%) enrolled in the lenalidomide/dexamethasone arm without anticoagulation developed thrombosis, including one ischemic stroke, while no events were reported in 9 patients assigned to the dexamethasone arm. 21 The addition of aspirin (80 mg or 325 mg) reduced such incidence to 19%. More contained DVT incidence was reported in a similar setting by Rajkumar 22 with aspirin prophylaxis (3%). Among other paraproteinemias, venous and arterial thrombotic events have been frequently associated with amyloidosis. In a group of 56 amyloidosis patients with a median age of 67 years, 11% developed VTE. 23 The presence of circulating monoclonal protein was not a risk factor for VTE development, whereas older age, immobility, and personal history of DVT were found to increase the thrombotic risk. In patients with acute leukemia and amyloidosis, a thrombotic event appears to confer a substantial morbidity and mortality and complicates the management of an already complex clinical condition: median survival for patients with arterial and venous thrombosis was 3 and thrombosis was 16 months respectively. 24 Recent studies indicate that cancer prothrombogenicity is involved intrinsically in tumor cell growth, angiogenesis, metastasis, and associated with a poorer prognosis. 25 These observations have led to the hypothesis that anticoagulant treatment could affect the survival of cancer patients. 26 We have analyzed the prognostic impact of the development of a thrombotic episode in newly diagnosed MM patients who received chemotherapy either with or without thalidomide on our Total Therapy 2 protocol. 27 Of 668 patients enrolled, 155 developed VTE complication during treatment. The overall and event-free survival of patients who experience VTE was not inferior. Indeed, we observed that patients who received intensive chemotherapy without thalidomide and developed thrombosis experienced a significantly longer event-free survival compared with those without VTE (p ¼ 0.02), suggesting a beneficial effect of low molecular weight heparin (LMWH) on disease progression. 28 
PATHOGENETIC MECHANISMS OF THROMBOSIS IN PARAPROTEINEMIAS
Multiple and interdependent mechanisms are responsible for the hypercoagulable state in patients with cancer. Tumor procoagulant activity, host inflammatory responses, and extrinsic factors, which frequently are iatrogenic, are involved. Classic risk factors such as surgery, prolonged immobilization, fractures, and use of oral contraceptives not only predispose apparently normal individuals to thrombosis but also are likely to trigger this condition in people with inherited and acquired thrombophilic abnormalities. Abnormally high plasma levels of immunoglobulin and associated increased blood viscosity can impair fibrin polymerization. 29 The abnormally structured fibrin interferes with the binding site for plasmin and factor XIII (FXIII). 30 Defective binding with FXIII causes a deficit in clot retraction and bulky clot formation, which can more easily occlude small blood vessels. 31 Abnormally assembled fibrin produces thinner and weaker strands that are more resistant to fibrinolytic activity of plasmin. In fact, fibrin structure is a major determinant of fibrinolysis that can be impaired in a manner dependent on the dose of immunoglobulin G (IgG). [32] [33] [34] Yagci et al 33 have observed a significant negative correlation between global fibrinolytic capacity (GFC) with levels of plasminogen activator inhibitor type 1 (PAI-1) and C-reactive protein (CRP), suggesting that decreased GFC is caused mainly by high PAI-1 activity. In MM, the increased PAI-1 activity seems to be related to an increased CRP and interleukin-6 (IL-6) levels. These observations indicate that inflammatory cytokines associated with myeloma (in particular, IL-6 and its downstream target CRP) not only have a direct effect on coagulation, but can also inhibit fibrinolysis. The monoclonal paraprotein itself may have intrinsic prothrombotic properties: several authors have described monoclonal paraproteins with lupus anticoagulant activity in patients who developed thromboembolic events. 35 Bellotti et al 36 described three patients with immunoglobulins against thromboplastin phospholipid that showed lupus anticoagulant-like activity: the strongest interaction was demonstrated in the patient with the most basic antibody. Takamiya et al 37 described an IgG lambda paraprotein derived from a myeloma patient with lupus anticoagulant-like activity in mixing studies; such immunoglobulin lost its activity when degraded by pepsin, suggesting that the interaction with coagulation factors and phospholipids was not immunologically mediated. These observations indicate that negatively charged immunoglobulins can interact with acid phospholipid on the platelet surface by an electrostatic mechanism. IL-6, CRP, and tumor necrosis factor alpha (TNF-a) are acute-phase reactant proteins frequently elevated in patients with MM.
IL-6 plays is an important role as a survival and antiapoptotic factor for MM cells in the bone marrow microenvironment and has been implicated in both autocrine and paracrine growth of the malignant clone. 38 IL-6 induces not only B lymphocyte differentiation into terminally differentiated plasma cells but also acts as a survival and growth factor for MM. IL-6 is able to induce the growth of plasma cells isolated from patients and to inhibit myeloma cell apoptosis induced by dexamethasone and anti-Fas antibodies, but it cannot inhibit apoptosis induced by irradiation. 39 Serum levels of IL-6 and CRP have been associated with the proliferative activity of the disease and used as prognostic factors in MM patients. 40 IL-6 is produced not only by plasma cells, but mainly by osteoblasts and stromal cells, resulting in paracrine stimulation of the malignant clone. This stimulation depends on both direct cell-cell contact and on the release of soluble factors such as TNF-a, soluble IL-6Ra, and vascular endothelial growth factor (VEGF). 41 The production of VEGF in this cytokine loop is of particular interest because VEGF enhances angiogenesis and upregulates the expression of tissue factor on endothelial cells, 42 thus contributing to the disease-associated thrombophilic state. Under normal conditions, the anticoagulant-to-procoagulant balance of the endothelium allows blood cells and platelets to flow without adhering to vessel walls. Excessive cytokine concentration during the inflammatory-or acute-phase response states can alter this fine balance, producing procoagulant endothelial conditions. 43 The cytokine network associated with MM also is an example of such an imbalance. In particular, elevated IL-6 levels are able to increase fibrinogen, tissue factor, and FVIII plasma levels. 44, 45 These in vitro observations also have been confirmed in the clinical setting, where high levels of FVIII and von Willebrand factor (vWF) antigen have been associated with IL-6 levels in patients with active disease. 46 In this background of impaired fibrinolysis and cytokine-induced activation of the coagulation system, the deficiency of natural anticoagulant mechanisms can further alter the hemostatic balance in a thrombophilic direction. In MM, an impaired activity of the protein C system has been suggested by the observation of abnormal resistance to activated protein C (APC) and by a reduced protein S function.
Indeed, the presence of acquired resistance to APC without FV Leiden mutation has been observed in cancer patients who experienced a thrombotic episode. 47, 48 After reporting a high incidence (23%) of acquired APC resistance in a group of 62 newly diagnosed myeloma patients with active disease, 49 we conducted an analysis of 1178 newly diagnosed or newly treated myeloma patients: APC resistance was detected in 109 patients (9%) and in two thirds of them the alteration was not related to FV Leiden mutation. 50 Patients carrying such an acquired abnormality developed a statistically higher incidence (p ¼ 0.008) of thrombosis during treatment. Acquired APC resistance was not observed in a series of 51 patients with MGUS that were tested at our institution (unpublished data) supporting the idea that cancer activity along with inflammatory cytokine release plays a crucial role in inducing abnormalities in the APC system. Similar experiences have been reported by Hugo and Jeanet, 51 who conducted a prospective study with 50 symptomatic MM patients treated with thalidomide in combination with VAD (20 patients), dexamethasone (24 patients), or melphalan/prednisone (six patients). 51 A transient acquired APC resistance was observed in 12% of patients and was associated with a high incidence (66%) of DVT.
Protein S is an important APC cofactor for the inactivation FVa and FVIIIa; levels of protein S are known to be reduced in inflammatory conditions. 52 Indeed, in a group of 78 newly diagnosed myeloma patients, we found a correlation between acquired APC resistance and decreased protein S activity (p ¼ 0.012), which was present in 27% of patients (Table 1) . 50 The binding of the IgG paraprotein with free protein S, which resulted in a severe acquired deficiency of protein S activity, has also been described in a myeloma patient. 53 The role of inherited thrombophilic factors seems to be marginal in patients with neoplasia 54 and in particular with MM. 55 In an analysis of 1178 myeloma patients conducted at our institution, 3% were carriers of the FV Leiden mutation. 50 FV Leiden mutation is the most common thrombophilic mutation that is found in 1 to 7% of a normal white population, 56 and determines a 7-fold increase of VTE risk in heterozygous carriers, whereas this risk is up to 80-fold higher in homozygous patients. 57, 58 In our series, patients carrying FV Leiden mutation appear to have higher VTE incidence compared with controls (22% v 12%), but this difference did not reach statistical significance. 50 The prothrombotic mutation 20210A of the prothrombin gene occurs in 2% of the general population, but it is more frequent in patients with VTE. 59 This mutation has been observed in 4% of newly diagnosed myeloma patients ( Table 2) . Methylenetetrahydrofolate reductase (MTHFR) gene *Thalidomide and dexamethasone were administered to newly diagnosed patients after an initial debulking chemotherapy.
R, relapsed/refractory; VTE, venous thromboembolism; N, newly diagnosed.
mutations have been described in up to 50% of MM individuals and overall not different from general population. 60, 61 In myeloma patients, inherited thrombophilic factors seem to have a marginal impact on VTE risk. Prophylactic strategies, and selected testing (APC) rather than extensive screening for thrombophilic factors are recommended in patients with paraproteinemias.
EFFECT OF MYELOMA THERAPY ON COAGULATION AND ANGIOGENIC FACTORS Activation of coagulation system and fibrinolysis, increased angiogenesis, and reduction of natural anticoagulants has been observed in patients with myeloma during the course of the disease (Table 1) . Several investigators reported transient elevations of FVIII and vWF levels during therapy with thalidomide. 46, 62 Minema et al 46 also described an association between FVIII and vWF levels and VTE development. Clinical evidence of an elevated plasma level of vWF and FVIII was described in a patient with hereditary von Willebrand disease type 2A, who experienced a temporary remission of bleeding symptoms at onset of MM. The reappearance of symptoms, after achieving remission, suggests that an effective myeloma therapy can downregulate the levels of these factors. 63 The knowledge of a correlation between FVIII levels and VTE risk 64 could be important for the assessment of the thrombotic risk of patients receiving thrombogenic therapies. Levels of vWF and platelet aggregation tests were obtained in a group of individuals at baseline and after therapy with liposomal doxo, vincristine, dexamethasone, and thalidomide. Higher vWF levels and increased platelet sensitivity to ristocetin during treatment suggest a possible interaction between platelets and endothelial cells. 65 The increased level of such factors could be related not only to therapy, but also could be associated with disease activity, given that many patients with active disease had elevated baseline FVIII and vWF levels, irrespective of thalidomide treatment. Because vWF is synthesized by endothelial cells, the level of vWF may indicate bone marrow neovascularization, or could be the result of cytokines release. Indeed, interleukin-11 upregulates clotting factor levels. 46 A group of 31 myeloma patients with acquired APC resistance had the test repeated at least twice during treatment. Response to therapy was associated with normalization of APC values in two thirds of these patients. Disease status (active disease versus partial or complete response) and level of monoclonal component were the two factors associated with the presence of APC resistance. 50 Reduction of thrombomodulin plasma concentration and variation of angiogenic factors also have been reported during thalidomide therapy 60, 66 (Table 2) . A decrease of VEGF and basic fibroblast growth factor (b-FGF) was only observed in responding patients. Similar changes in angiogenic molecules were also described with conventional chemotherapy, indicating that tumor burden reduction rather than thalidomide-dependent inhibition of angiogenic cytokine secretion is the most likely explanation for this phenomenon. In a bone marrow endothelial cell system derived from active myeloma patients, thalidomide has been shown to downregulate the expression of angiogenic genes such as VEGF, b-FGF, and hepatocyte growth factor. A similar effect was not observed on endothelial systems derived from inactive MM or monoclonal gammopathy. 67 It is conceivable that the antiangiogenic properties associated to thalidomide are depending on the disease and microenvironment, explaining the contrasting results obtained regarding the antiangiogenic activity of thalidomide in vivo.
EFFECT OF ANTICOAGULANTS ON THROMBOTIC COMPLICATIONS IN PARAPROTEINEMIAS
The best strategy to prevent thromboembolic complications in paraproteinemias has not been established yet, mainly because of limited data available. Although it is difficult to introduce a systematic thromboprophylaxis in a population of patients who are often thrombocytopenic and have an increased risk of bleeding, the high rate of thromboembolic complications during the treatment with new agents warrants the use of prophylaxis in those patients with the highest risk. Definition of the treatment-associated thrombotic risk in a specific cancer population and identification of reliable markers for VTE development are fundamental for the evaluation of the risk-benefit ratio of an anticoagulant therapy. Table 2 summarizes the strategies for thromboprophylaxis used in myeloma patients treated with thalidomide and lenalidomide in different combinations with dexamethasone or chemotherapy. Effective anticoagulation with warfarin has the advantage of oral administration, but it requires regular monitoring to keep international normalized ratio (INR) values within a defined range and it has many interactions with food or other drugs. With the use of therapeutic anticoagulation with warfarin (INR range 2 to 3), thrombosis was a rare event in newly diagnosed patients treated with thalidomide and dexamethasone. 68 The use of fixed low-dose warfarin derives from the experience in VTE prophylaxis for patients with indwelling catheters or with atrial fibrillation. Although this strategy does not require blood monitoring, efficacy results were contrasting. 69, 70 Similar opposing results were obtained in MM: Although Cavo et al 12 showed a significant reduction in VTE incidence in newly diagnosed patients treated with upfront thalidomide and dexamethasone, Weber et al 68 and Zangari et al 71 did not confirm this risk reduction. Different doses of warfarin (1.25 versus 1 mg/d) or different patient populations may account for the discordant results.
The superiority of LMWH compared with warfarin for recurrent VTE prophylaxis in cancer patients 72 inspired the use of these drugs for thromboprophylaxis in MM patients with the highest VTE risk.
The prothrombotic effect of doxo-containing chemotherapy combined with thalidomide was abrogated completely by the prophylactic use of enoxaparin (40 mg/d) or nadroparin (2850 IU anti-Xa), as listed in Table 2 . 71, 73 For the treatment of responding patients who developed VTE, available data suggest that it is reasonable to resume the therapy with thalidomide when full anticoagulation has been established and continued for the total duration of therapy. 71 The rate of VTE recurrence was overall 11% and not significantly different from the rate observed in other cancers (9 to 17%). 74 Recent data suggesting a possible role of platelet dysfunction in the pathogenesis of VTE have led to test aspirin as thromboprophylaxis in clinical trials. 65 Although only a modest reduction of VTE incidence was obtained with prophylactic fixed low dose aspirin in patients treated with thalidomide, dexamethasone and chemotherapy, 75 aspirin appears more efficacious in protocols including lenalidomide/dexamethasone, as shown in Table 2 . 21, 22 BLEEDING DIATHESIS IN PARAPROTEINEMIAS Evidence of bleeding, often confined to purpura, epistaxis, or hematuria, manifests in less than 10% of patients with MGUS, MM, Waldenström macroglobulinemia, and primary AL amyloidosis. Interactions between plasma paraprotein, platelets, and coagulation factors (reviewed by Liebman 76 ) are the common pathophysiologic mechanisms.
In a series of 62 patients with paraproteinemia, correlation between specific immunoglobulins and abnormalities of the coagulation system or frequency of bleeding episodes were described. 77 Platelet count and thrombin time were more frequently altered in IgG and IgA paraproteinemias, whereas platelet adhesiveness test, FVIII levels, prothrombin time (PT), and partial thromboplastin time (PTT) were often abnormal in IgA and IgM paraproteinemias. Bleeding episodes were more frequent in Waldenström macroglobulinemia (36%) and IgA myeloma (33%). Mixing studies with normal plasma indicated the presence of an inhibitory paraprotein that caused reduced levels of coagulation factors or prolongation of thrombin time (TT), PT, and PTT times.
Bleeding diathesis is more commonly observed in patients with amyloidosis: at diagnosis, 15% of patients show purpura, particularly in periorbital and facial areas. 78 Severe hemorrhages are rare, but they can be life threatening. In a series of 36 patients with amyloidosis and monoclonal gammopathy, laboratory clotting abnormalities were found in most cases and hemorrhagic manifestations were found in one third of patients (nine mild to moderate episodes of purpura or ecchymoses and fatal mucosa hemorrhage). 79 Prolongation of TT, reptilase time (RT), and Russel viper venom time (RVVT) are the most common abnormalities found; low plasma levels of FX are also common and do not correlate with RVVT. The presence of a plasma inhibitor has been hypothesized to be the cause of TT, RT, and RVVT prolongation but abnormal tests values can also be observed in the absence of an abnormal paraprotein. Paraprotein can inhibit fibrin polymerization, resulting in prolonged TT and abnormal clot formation. 30 Inhibition of fibrin monomer aggregation by the paraprotein also has been postulated in a patient with MM with prolonged TT and RT, where TT but not RT was corrected by the mixing of patient's and normal plasma. 80 Despite the relatively frequent abnormal TT time, clinical bleeding manifestations are observed only in a minority of patients, who possibly have other associated hemostatic defects, such as a decreased FX level, enhanced fibrinolysis due to a 2 -antiplasmin deficiency, 79 or vessel wall amyloid deposition. 81 The primary role of plasma factors in the bleeding diathesis is also suggested by the clinical response observed with plasma exchange or large-volume plasmapheresis, in particular in patients with Waldenström macroglobulinemia. 82, 83 The presence of circulating paraproteins with vWF or FVIII inhibitory activity have been described in patients with MGUS, 84 MM, Waldenström macroglobulinemia, lymphoma, chronic lymphocytic leukemia, and amyloidosis. 85, 86 The presence of such factors was associated with clinical symptoms of acquired von Willebrand disease or hemophilia. 87, 88 The addition of purified paraprotein to plateletrich plasma can impair platelet aggregation and release of platelet factor 3. 89, 90 A lambda dimeric protein purified in a patient with IgD/lambda myeloma, who rapidly developed a subcutaneous hematoma after puncture of the inguinal artery, retained the ability to prolong PTT and RVVT and to inhibit ristocetin-induced platelet aggregation. 91 This lambda dimer showed both lupus anticoagulant activity and inhibitory effect on vWF glycoprotein Iba binding on the platelet surface, inducing an acquired von Willebrand state. 91 The coexistence of these two hemostatic alterations caused by the same monoclonal protein is rare, but it has been observed in several cases of paraproteinemias. 84 Other paraprotein-independent mechanisms can determine laboratory or clinical hemostatic abnormalities. Heparin-like anticoagulants have been identified in patients with MM with a prolonged TT, which was corrected by addition of heparinase or protamine sulfate; the latter was also able to control bleeding in one patient. 92, 93 Excessive fibrinolysis has been reported in several cases of MM and amyloidosis that manifested bleeding diathesis and abnormal coagulation tests, such as shortened clot lysis and elevated fibrin/fibrinogen degradation products. 94 The pathogenesis of hyperfibrinolysis could be related to a reduced levels of a 2 -antiplasmin or may be secondary to complex formation with plasmin; increased urokinase-type plasminogen activator activity also has been observed in a few other cases. 95 Treatment with e-aminocaproic acid was efficacious in controlling bleeding symptoms in some patients. 96 Accelerated clearance of coagulation proteins can explain the hemostatic abnormalities in same cases. An increased binding of vWF with monomeric IgM on the surface of malignant cells has been described to induce acquired von Willebrand disease in a patient with Waldenström macroglobulinemia. 97 Bleeding symptoms associated to acquired deficiency of FX is a relatively common feature in amyloidosis. 98 No evidence of a FX inhibitor was demonstrated, but a rapid clearing from circulation of I 131 -labeled FX and accumulation in areas involved by amyloid deposits were shown by Furie et al. 99 Quantitative affinity chromatography analysis demonstrated that FX binds frequently to amyloid fibrils in the spleen. 100, 101 Splenectomy can produce resolution of bleeding diathesis in some cases. 102, 103 Hemorrhagic symptoms, in particular retinal hemorrhages, epistaxis, and gingival bleeding, are characteristic of the hyperviscosity syndrome, frequently observed in Waldenström macroglobulinemia and less commonly in MM. 104 Plasma exchange is an effective treatment to reduce plasma viscosity and bleeding.
CONCLUSIONS
Hemostatic dysfunctions leading to thrombotic or hemorrhagic complications are common in patients with paraproteinemias and amyloidosis. The use of antiangiogenic agents in combination with steroids or chemotherapy further enhances the thrombotic risk.
The inflammatory response associated with these conditions and reduced natural anticoagulant mechanisms are important factors that determine the thrombophilic state, even though specific paraprotein-linked effects (such as lupus anticoagulant activity or inhibition of fibrin polymerization) also are involved in several cases. The coagulation abnormalities that are more frequently observed in the presence of active disease can normalize with effective treatment. Emerging data indicate that the effect of LMWH in cancer and in MM is not confined to the anticoagulant activity but extends to survival. 
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